FDA Approves Labeling Update for REYATAZ ® (atazanavir sulfate) Capsules to Include 96-Week Data for Previously Untreated HIV-1 Infected Adult Patients

FDA Approves Labeling Update for REYATAZ ® (atazanavir sulfate) Capsules to Include 96-Week Data for Previously Untreated HIV-1 Infected Adult Patients

Business Wire - 25 minutes ago
PRINCETON, NJ--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the US Food and Drug Administration (FDA) has approved a labeling update for REYATAZ ® to include long ...
FDA Approves Labeling Update for REYATAZ(R) (atazanavir sulfate) Capsules to Include 96-Week Data for Previously Untreated HIV-1 Infected Adult Patients - Stockhouse